2026-04-30
Over the past 16 months, Chinese biotechs have featured in ~6 of every 26 major pharma deals, accounting for nearly one-third of total value. Major licensing pacts include Merck with Hansoh and Hengrui, Pfizer with 3SBio, AstraZeneca with CSPC (twice), AbbVie with RemeGen, Sanofi with Sino Biopharm, and Lilly with Insilico. In 2025, China led global new drug launches for the first time, surpassing the U.S. McKinsey cites China’s R&D speed and cost advantages...